Pharmaceuticals company Caplin Point Laboratories announced Q1FY24 results: Revenue for Q1FY24 grew by 13.1% YoY to Rs 407 crore Gross margin for Q1FY24 is at 54.8% EBITDA for Q1FY24 is Rs 139 crore; EBITDA margins at 34.0% Q1FY24 PAT is at Rs 104 crore up 20.8% YoY Cash and cash equivalents at Rs 808 crore as of June 30, 2023 Cash flow from operations at Rs 88 crore for Q1FY24; Capex for Q1FY24 is at Rs 51 crore; Free cash flow for the period was Rs 37 crore Basic EPS grew by 21% to Rs 13.62 in Q1FY24 against Rs 11.21 in Q1FY23 Receivable stood at 97 days Geographical breakup of sales: LATAM & ROW 88%, US 12% Commenting on the performance, C.C. Paarthipan, Chairman, said, “We are particularly pleased with the robust growth in our Latin America business, both in terms of revenue and profitability which also resulted in robust margins. The expansion of Softgel capacity at our CP-1 site has strengthened our position in this market, with a quick payback. Coming to the US, with a strong order book, we are optimistic about achieving 40-50% revenue growth in FY24. We aim to achieve this growth through strategic new product launches and by increasing our market share for existing products. Overall, we remain committed to driving sustainable growth and delivering value to all our stakeholders.” Result PDF
